本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

阿玛琳

18.94
-0.3000-1.56%
盘后19.750.8100+4.28%19:51 EDT
成交量:9.99万
成交额:188.99万
市值:3.92亿
市盈率:-3.77
高:19.24
开:19.24
低:18.50
收:19.24
52周最高:20.90
52周最低:7.08
股本:2,068.28万
流通股本:1,875.61万
量比:0.47
换手率:0.53%
股息:- -
股息率:- -
每股收益(TTM):-5.0205
每股收益(LYR):-3.9998
净资产收益率:-20.38%
总资产收益率:-4.35%
市净率:0.84
市盈率(LYR):-4.74

数据加载中...

公司资料

公司名字:
阿玛琳
交易所:
NASDAQ
成立时间:
1989
员工人数:
- -
公司地址:
One Central Plaza,5th Floor,36 Dame Street,Dublin,Co. Dublin,Ireland
邮编:
D02 K7K5
传真:
- -
简介:
Amarin Corporation Plc于1989年3月1日在英国注册成立。该公司是一家专注于改善心血管或心血管健康和降低心血管风险的疗法商业化和开发的制药公司。该公司商业化的产品,VASCEPA首先获得美国,或美国,食品和药物管理局,或美国FDA的批准,用于作为饮食的辅助,以降低成人重症(≥ 500mg/dL)高甘油三酯血症患者的甘油三酯或TG水平,或海洋适应症。

董事

名称
职位
Aaron D. Berg
Director,President and Chief Executive Officer
Odysseas Kostas
Director and Chairman of the Board
Diane Sullivan
Director
Keith L. Horn
Director
Louis Sterling III
Director
Michael Torok
Director
Oliver O'Connor
Director
Patrice Bonfiglio
Director
Paul Cohen
Director

股东

名称
职位
Aaron D. Berg
Director,President and Chief Executive Officer
David Keenan
Executive Vice President, Chief Operating Officer
Peter L. Fishman
Senior Vice President, Chief Financial Officer and Principal Accounting Officer
Jonathan N. Provoost
Executive Vice President, Chief Legal & Compliance Officer and Secretary
Steven B. Ketchum
Executive Vice President, President of R&D and Chief Scientific Officer